Cancer Immunotherapy Market Size, Share Report, 2026-2034
REPORT DETAILS
Cancer Immunotherapy Market Summary and Key Insights
The global cancer immunotherapy market was valued at USD 152.55 billion in 2025 and is expected to grow at a CAGR of 8.98% from 2026 to 2034. The market is driven by the increasing prevalence of cancer and the efficacy of immunotherapy treatments over traditional methods.
Market Statistics
Key Takeaways
- North America dominated the market and accounted for nearly 46.80% revenue share in 2025. The presence of major market participants and increased investments in cancer immunotherapies drive the regional market growth.
- The U.S. led the North America market with approximately 71.40% share in 2025. Rising healthcare expenditures and the availability of comprehensive medical insurance bolster the U.S. market growth.
- The Asia Pacific cancer immunotherapy market is expected to register the highest CAGR of around 12.60% during the forecast period. The growth is attributed to the rising cancer prevalence and the introduction of patient assistance programs (PAPs).
- The monoclonal antibodies segment dominated with nearly 49.30% revenue share in 2025. Increasing R&D activities in genomics and growing technological advancements fuel the segment's growth.
- The hospitals segment is anticipated to record a CAGR of approximately 11.80% during the forecast period, driven by the rising number of hospital admissions for cancer treatment.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Rising prevalence of cancer across the world drives the growth of the market.
- Increasing awareness of immunotherapy for cancer management fuels the market expansion.
- High cost of immunotherapy is a major restraining factor for the market expansion.
- Surging emphasis on advancements in immunology is expected to create lucrative opportunities in the market.
- Growing investments in cell-based immunotherapies, such as CAR-T and TCR therapies, would become a future key trend.
Industry Trends
Immunotherapies are biotherapy, also known as biologic therapy or biological response modifier (BRM) therapy. They use substances from living organisms to combat illness. Certain Immunotherapy treatments utilize genetic engineering to boost the cancer-fighting abilities of immune cells, which can be referred to as gene therapies. The purpose of Immunotherapy drugs is to enhance the immune cells' ability to fight cancer, thereby providing the immune system with an advantage. Immunotherapy has been an effective treatment for patients with certain types of cancer resistant to chemotherapy and radiation treatment.
Source: Polaris Market Research Analysis
To Understand More About this Research:Download Sample Report
The increasing incidence of cancer is a major factor in the growth of the cancer Immunotherapy market. Moreover, the expanding effectiveness and accuracy of newer therapies, the rising adoption of target therapy over traditional medicine, and increasing R&D activities for new drug development collectively influence the market growth. As per the NCT Registry, as of September 8, 2020, over 1,000 clinical trials are currently underway worldwide in various phases of development for treating cancer with immune-based therapies. Additionally, with the ongoing development of these therapies, if trials continue to yield positive results, players can anticipate the emergence of new and effective immuno-therapies for cancer.
The cost of cancer Immunotherapy research and development poses a significant challenge for players in developing countries, making it difficult to secure sufficient funds for treatment. Implementing new innovations to enhance research also demands substantial investment. However, due to the high costs involved in cancer Immunotherapy, major companies are apprehensive about entering this market as they are uncertain about potential profitability. These factors collectively act as a restraining factor on the growth of the global cancer Immunotherapy market.
Cancer Immunotherapy vs. Chemotherapy: Efficacy, Safety and Use Cases
| Factor | Cancer Immunotherapy | Chemotherapy |
| Treatment Approach | Activates the immune system | Directly kills rapidly dividing cells |
| Target | Cancer cells through immune response | Cancer and healthy fast-growing cells |
| Mechanism | Boosts immune cell activity | Blocks cancer cell growth and division |
| Side Effects | Mainly immune-related effects | Broader systemic side effects |
| Treatment Duration | May provide durable responses | Usually requires repeated treatment cycles |
| Application | Targeted and personalized therapies | Broad use across many cancer types |
| Patient Suitability | Selected patients based on biomarkers | Suitable for a wide range of patients |
Source: Polaris Market Research Analysis
What Is Cancer Immunotherapy?
Cancer immunotherapy is a treatment that involves the use of patient's body’s own immune system to fight cancer. The system doesn’t directly attack tumors like traditional treatments. These therapies activate or strengthen immune cells. Thus, they can recognize and destroy cancer cells more effectively.
How Cancer Immunotherapy Works Against Tumors
- Cancer cells resist immune detection
- Immunotherapy activates the immune response
- Immune cells identify cancer-specific markers
- These cells attack and destroy cancer cells
- Tumor growth is controlled
- Treatment response is monitored continuously
Cancer Immunotherapy Technology Trends and Innovations
| Technology | Advancement | Benefit |
| CAR T-cell Therapy | Genetically engineered T cells target cancer cells | Improves outcomes in blood cancers |
| Immune Checkpoint Inhibitors | PD-1, PD-L1, and CTLA-4 blockade therapies | Enhances immune response against tumors |
| Biomarker Testing | Precision diagnostics for patient selection | Facilitates personalized treatment decisions |
| Next-Generation Monoclonal Antibodies | Improved targeting and engineered antibody designs | Improves treatment effectiveness |
| Cancer Vaccines | Personalized and neoantigen-based vaccine development | Stimulates targeted anti-tumor immunity |
| AI and Genomics | AI-driven biomarker discovery and genomic analysis | Boosts therapy development and precision medicine |
Source: Polaris Market Research Analysis
Cancer Immunotherapy Market Drivers and Opportunities
What Factors Are Driving Cancer Immunotherapy Market Growth?
Rising Global Cancer Incidence and Immunotherapy Adoption
The rising number of cancer patients has significantly influenced the growth and expansion of the cancer Immunotherapy market. Cancer continues to be a leading cause of morbidity and mortality worldwide, with billions of new cases diagnosed each year. This increasing burden of cancer has spurred the urgent need for more effective and targeted treatment options, giving rise to the rapid development and adoption of cancer Immunotherapy.
One of the key drivers behind the growth of the cancer Immunotherapy market is the success of immune checkpoint inhibitors. These drugs have shown remarkable efficacy in various cancer types, including melanoma, lung cancer, and renal cell carcinoma. Immune checkpoint inhibitors work by blocking certain molecules on immune cells, allowing them to recognize and attack cancer cells that might otherwise evade detection. The clinical success and approval of these therapies have opened new avenues for research and investment in the field of cancer Immunotherapy.
Cancer Immunotherapy Market Restraints and Challenges
High Treatment Cost and Limited Patient Access
High treatment cost is representing a substantial challenge in the widespread adoption and accessibility of these innovative therapies. The cost of developing, manufacturing, and administering cancer immunotherapies presents obstacles for patients, healthcare providers, and healthcare systems. This factor has multifaceted implications that impact various stakeholders within the market.
Developing new cancer immunotherapies requires extensive research, ranging from early-stage discovery to preclinical and clinical trials. These stages involve substantial financial investments to identify and optimize therapeutic targets, develop suitable drug candidates, and demonstrate their safety and efficacy. The complexity of understanding the immune system's interactions with cancer cells contributes to the high cost of research. The absence of cost-effective generic alternatives limits price competition, contributing to high costs. High costs can create barriers to cancer immunotherapies, particularly for patients without adequate insurance coverage or in regions with limited healthcare resources. This limitation disproportionately affects individuals from lower socioeconomic backgrounds.
Cancer Immunotherapy Adoption Challenges
| Challenge | Impact |
| Immune-Related Adverse Effects | Inflammation and autoimmune reactions are a few adverse effects. They require close patient monitoring and treatment management. |
| Limited Response Rates | Immunotherapy does not suit all patients. Thus, biomarker-based patient selection becomes essential. |
| Regulatory Approval Timelines | Time-consuming clinical trials and regulatory reviews delay product commercialization and market entry. |
| High Treatment Costs | High costs of therapies limit affordability and patient access, especially in developing regions. |
| Biomarker Identification Challenges | Limited availability of reliable biomarkers adversely impact patient selection and treatment outcomes. |
| Manufacturing Complexity | CAR-T therapy and other cell-based treatments require specialized production processes. It increases costs and supply challenges |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Cancer Immunotherapy Market Segment Analysis
The market is primarily segmented based on type, application, end-user, and region.
| By Type | By Application | By End-User | By Region |
|
|
|
|
Source: Polaris Market Research Analysis
Category Wise Insights
By Type Insights
Based on type category analysis, the market has been segmented on the basis of monoclonal antibodies, cancer vaccines, and check point inhibitors & immunomodulators. In 2023, monoclonal antibodies emerged as the dominant segment in the global market because these specialized antibodies are designed to target specific molecules on either cancer cells or immune cells, facilitating the immune system's ability to recognize and combat cancer more effectively. By focusing on targeted interactions, mAbs offer a notable advantage over conventional chemotherapy, reducing harm to healthy cells and minimizing side effects.
Some of the mAbs' Applications in cancer Immunotherapy involve immune checkpoint inhibitors, a well-recognized category. These antibodies obstruct certain proteins like PD-1, PD-L1, and CTLA-4, hindering the immune response against cancer cells. This interference empowers the immune system to mount a robust defense against cancer. Additionally, mAbs are pivotal in cutting-edge Chimeric Antigen Receptor T-cell (CAR-T) therapy. By engineering a patient's T cells to express synthetic receptors (CARs) that pinpoint specific cancer cell antigens, mAbs contribute to this groundbreaking approach.
Checkpoint Inhibitors and Adoptive Cell Therapies
Checkpoint inhibitors and CAR-T cell therapy are the forefront of immunotherapy in cancer management. Checkpoint inhibitors help reactivate the immune system. With this, the system recognizes cancer cells.
CAR-T cell therapy involves genetic modifications of immune cells. The cells target particular antigens in cancer cells. CAR-T cell therapy is particularly preferred for a few leukemias, lymphomas, and multiple myeloma treatments. The therapy is effective, especially in relapsed or refractory cases. PD-1/PD-L1 Inhibitors, CTLA-4 Inhibitors, and combinational treatments are preferred increasingly. They have brought about changes in treatment efficacy.
By End-User Insights
Based on end-user category analysis, the market has been segmented on the basis of hospitals, clinics, and cancer research centers. The hospitals segment is anticipated to grow with a significant CAGR in the forecasted years. Increased healthcare expenditure has directed to a rise in the use of Immunotherapy drugs in hospitals and clinics worldwide. The growing number of multispecialty hospitals reflects the efforts of various countries to enhance the quality of healthcare services for patients, resulting in increased demand for advanced solutions like cancer Immunotherapy for early cancer treatment.
The hospitals in cancer Immunotherapy market projected to maintain its dominance during the forecast period. It is due to the increased number of hospital admissions related to cancer treatment and the growing presence of government and private hospitals, which are the preferred choice for patients seeking treatment for various cancer types. The rising penetration of hospitals and the adoption of advanced treatment technologies are expected to fuel the segment's growth further.
Cancer Immunotherapy Market, by Cancer Type
| Application | Real-World Example |
| Advanced lung cancer treatment | Immune checkpoint inhibitors are used for advanced lung cancer treatment. The therapy improves the body's immune response against tumors. |
| Melanoma management | Immune-based therapies are preferred to treat advanced melanoma. The therapies improve survival and reduce disease progression. |
| Blood cancer treatment | Preference for CAR T-cell therapy is high to treat leukemia, lymphoma, and multiple myeloma patients with relapsed or refractory disease. |
| Personalized cancer care | Tumor biomarkers and genetic characteristics are studied to enable targeted personalized immunotherapies. |
| Alternative to conventional therapy | Some patients do not respond adequately to chemotherapy. In such cases, immune-based treatment options are selected. |
| Long-term disease control | Enhancement of durable immune responses and reduction of recurrence risk. Improves long-term cancer treatment outcomes. |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Cancer Immunotherapy Market Regional Analysis
Regional Market Trends
| Region | Market Position | Market Trends |
| North America | Leading market | Rising emphasis on advancements in oncology research and high adoption of immunotherapy treatments |
| Europe | Second-largest market | Increasing cancer research initiatives, favorable reimbursement policies, and expanded access to innovative immunotherapy treatments. |
| Asia Pacific | Fastest-growing market | Expanding healthcare infrastructure, growing healthcare investments, and high adoption of advanced immunotherapies |
| Latin America & Middle East & Africa | Emerging market | Improvements in healthcare access, surging cancer awareness, and gradual adoption of advanced oncology therapies |
Source: Polaris Market Research Analysis
North America
North America accounted for a significant revenue share in the global market due to the enhanced accessibility to advanced cancer immunotherapies for patients, the presence of prominent market participants, and escalated investments in cancer immunotherapies by both governmental and non-governmental entities are pivotal factors propelling the market's advancement in North America. The region's progressively aging population is another noteworthy contributor to its market expansion, while the burgeoning presence of pharmaceutical and biotechnological firms further amplifies regional market development. The influence of well-established market leaders is decisive in propelling revenue growth. The swift uptake of immunotherapies within this region also augments the increase in market revenue. Additional forces fueling this revenue surge encompass enhancements in healthcare infrastructure, escalating healthcare expenditures, and the availability of comprehensive medical insurance, particularly in developed nations such as the U.S. and Canada.
Asia Pacific
The Asia-Pacific cancer immunotherapy market is predicted to expand significantly due to the rising incidence of cancer, government initiatives to increase public awareness of the disease, and the development of patient assistance programs (PAPs). Esophageal cancers, Lung, colorectum, stomach, liver, and are the most common in Asia-Pacific. For example, a study titled "Burden of Cancers in India - Estimates of Cancer Incidence for 2021 and 2025 based on the National Cancer Registry Program" forecast that the region will see 26.7 billion new cancer cases in 2021. That number would rise to 29.8 billion in 2025. As a result of the increased incidence of cancer, the market will grow throughout the forecast period.
Source: Polaris Market Research Analysis
Cancer Immunotherapy Market Competitive Landscape
The market showcases a vibrant and competitive landscape, driven by the critical need for more effective cancer treatments and the remarkable potential of immunotherapy in combating various cancer types. Key players dominate the market with their extensive portfolios of immunotherapeutic drugs. Additionally, biotechnology companies are actively investing in research and development to bring innovative immunotherapies to market.
Leading Cancer Immunotherapy Companies
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca
- Bayer AG
- Bristol Myers Squibb
- Eli Lilly
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Novartis AG
- OSE Immunotherapeutics
Cancer Immunotherapy Market Recent Developments
- January 2026: BioNTech SE announced that the U.S. FDA had granted Fast Track designation to its BNT113. It is an investigational mRNA cancer immunotherapy. The therapy can be used to treat patients of human papillomavirus type 16 positive (“HPV16+”) head and neck squamous cell carcinoma (“HNSCC”) expressing PD-L1. (Source: biontech.com)
- In January 2025, AbbVie partnered with Simcere Zaiming to jointly develop a novel trispecific antibody candidate aimed at treating multiple myeloma.
- In May 2024, Amgen announced that the FDA approved IMDELLTRA™ (tarlatamab-dlle), the first T-cell engager therapy for extensive-stage small cell lung cancer, following strong clinical results showing a 40% response rate and 14.3-month survival.
Cancer Immunotherapy Market Future Outlook
As per our research, the market will witness substantial growth during the forecast period. Healthcare systems are increasingly adopting immune-based cancer treatments. Further, pharmaceutical companies are developing innovative therapies. Increasing preference for checkpoint inhibitors, CAR T-cell therapies, and personalized oncology would boost the market development. Biomarker discovery and combination treatment approaches would become key industry trends. Advances in biotechnology and precision medicine enable lead to effective and targeted therapies. It will continue transforming cancer care in the future.
Cancer Immunotherapy Market Report Coverage and Methodology
The cancer immunotherapy market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, type, application, end-user, and their futuristic growth opportunities.
Cancer Immunotherapy Market Report Scope
| Report Attributes | Details |
| Market size value in 2025 | USD 152.55 billion |
| Market size value in 2026 | USD 166.1 billion |
| Revenue forecast in 2034 | USD 330.73 billion |
| CAGR | 8.98% from 2026 – 2034 |
| Base year | 2025 |
| Historical data | 2021 – 2024 |
| Forecast period | 2026 – 2034 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments covered | By Type, By Application, By End-User, By Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Customization | Report customization as per your requirements with respect to countries, region, and segmentation. |
Source: Polaris Market Research Analysis
Cancer Immunotherapy Market Frequently Asked Questions
The global cancer immunotherapy market is expected to reach approximately USD 673.08 billion by 2034, driven by rising cancer prevalence and therapeutic innovation.
In 2025, the cancer immunotherapy market was valued at USD 152.55 billion, reflecting strong demand for targeted and immune-based cancer therapies.
The market is forecast to grow at a CAGR of 8.98% from 2026 through 2034, supported by expanding R&D and increased adoption of novel immunotherapies.
Growth is propelled by rising cancer incidence globally, expanding clinical approvals, technological advances, and heightened R&D investments in immunotherapy drug development.
Market trends may be influenced by regulatory approvals, personalized treatment adoption, healthcare infrastructure expansion, and advances in immuno-oncology.
Immune checkpoint inhibitors are immunotherapy drugs that block proteins such as PD-1, PD-L1 or CTLA-4, helping immune cells identify and attack cancer cells.
CAR T-cell therapy comprises a genetic engineering of patient's own T-cells. They are modified to target a specific cancer protein. Then these cells are infused back to seek out and destroy tumors.
Personalized immunotherapy offers new and alternate cancer treatment options. It involves the customized treatment based on unique tumor genetics, biomarkers, and immune profile in mind. In this, the patient's medical history and regulatory guidelines are being considered. Personalized treatment offers better effectiveness. It also lowers the risks of side effects and resistance.
Download Sample Report of Cancer Immunotherapy Market
Please fill out the form to request a customized copy of the research report.
